ClinicalTrials.govpublic full text
Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat
metastatic head and neck squamous cell carcinoma, recurrent head and neck squamous cell carcinoma, unresectable head and neck squamous cell carcinoma, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 861869
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.